AbbVie Inc.は好調な収益を報告し、配当を引き上げましたが、ある主要投資家の持分はわずかに減少しました。 AbbVie Inc. reported strong earnings, raised its dividend, yet saw a slight drop in one major investor's stake.

Canandaigua National Bank & Trust Co.は、AbbVie Inc.の株式を1.5%削減しましたが、Oliver Luxxe Assets LLCなどの他の投資家は持ち株を増やしました。 Canandaigua National Bank & Trust Co. reduced its stake in AbbVie Inc. by 1.5%, while other investors like Oliver Luxxe Assets LLC increased their holdings. AbbVieは強い四半期を報告し,EPSの予測を0.08ドルで突破し,その四分の一を1.64ドルに増額した. AbbVie reported a strong quarter, beating EPS estimates by $0.08, and raised its quarterly dividend to $1.64, a 3.65% yield. 薬剤会社で有名なフミラ (Humira) の市場総額は317780億ドルで 価格対収益比は62.44です The pharmaceutical company, known for its drug Humira, has a market cap of $317.78 billion and a price-to-earnings ratio of 62.44. アナリストはAbbVieに"適度な買い"の評価を与え,平均価格目標額は205.70ドルである. Analysts have given AbbVie a "Moderate Buy" rating with an average price target of $205.70.